Beijing-based Concord Medical is ready to list on the New York Stock Exchange next week, where it aims to raise up to US$157 million from 12 million shares priced between US$9.50 and US$11.50, the Wall Street Journal reported. The company claims to operate the largest network of radiotherapy and diagnostic imaging centers in China. Concord Medical’s specialty is cancer treatment, and its growth has been driven by China’s burgeoning rate of cancer, which was the leading cause of death in the country last year. The company also stands to benefit from increased health care spending by the central government. In the first nine months of 2009, Concord Medical generated US$30 million in net revenues. However, the company has warned that growth could plateau in the future; it operates its centers under long-term lease and management service agreements with partner hospitals, but few top-tier hospitals have yet to enter agreements with it or one of its competitors. In addition, Beijing limits the amount and types of radiology equipment hospitals can purchase.